The financial burden of cancer care: Do patients in the US know what to expect?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 6, 2014, Pages 835-842

  Peppercorn, Jeffrey ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

Cancer; Costs; Financial burden; Medical decision making; Patient education

Indexed keywords

AWARENESS; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HEALTH CARE QUALITY; HUMAN; PATIENT CARE; PATIENT EDUCATION; REVIEW; UNITED STATES; ATTITUDE TO HEALTH; COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; HEALTH CARE PLANNING; HEALTH PERSONNEL ATTITUDE; NEOPLASMS; UTILIZATION;

ATTITUDE OF HEALTH PERSONNEL; AWARENESS; COST OF ILLNESS; COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH RESOURCES; HUMANS; NEOPLASMS; PATIENT EDUCATION AS TOPIC;

EID: 84909956638     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.963558     Document Type: Review

References (61)

1. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011;12(10):933-80
2. Keehan SP, Sisko AM, Truffer CJ, et al. National health spending projections through 2020: economic recovery and reform drive faster spending growth. Health Aff (Millwood) 2011;30(8):1594-605
3. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 2013;32(6):1143-52
4. Zafar SY, Peppercorn JM, Schrag D, et al. The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience. Oncologist 2013
5. U.S. Census Bureau, Statistical Abstract of the United States: 2012 (131st Edition) Washington, DC, 2011. Available from: www.census.gov/compendia/statab/
6. DeNavas-Walt C, Proctor BD, Smith JC. Income, Poverty, and Health Insurance Coverage in the United States. BUREAU USC, editor. 2012
7. Schoen C, Hayes SL, Riley P. The Affordable Care Act's new tools and resources to improve health and care for low-income families across the country. Issue Brief (Commonw Fund) 2013;26:1-14
8. Young RA, DeVoe JE. Who will have health insurance in the future? An updated projection. Ann Fam Med 2012;10(2):156-62
9. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013;119(6):1257-65
10. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 2011;20(10):2006-14
11. World Development Indicators database, World Bank. Database updated on 1 July 2014. Available from: http://data.worldbank.org/data-catalog/world-development-indicators [Last accessed 5 August 2014]
12. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013;14(12):1165-74
13. Syse A, Tretli S, Kravdal O. The impact of cancer on spouses' labor earnings: a population-based study. Cancer 2009;115(18 Suppl):4350-61
14. Mehnert A, de Boer A, Feuerstein M. Employment challenges for cancer survivors. Cancer 2013(119 Suppl 11):2151-9
15. Earle CC, Chretien Y, Morris C, et al. Employment among survivors of lung cancer and colorectal cancer. J Clin Oncol 2010;28(10):1700-5
16. Hassett MJ, O'Malley AJ, Keating NL. Factors influencing changes in employment among women with newly diagnosed breast cancer. Cancer 2009;115(12):2775-82
17. Peppercorn J, Zafar SY, Houck K, et al. Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol 2014;15(3):e132-8
18. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366(2):109-19
19. Babigumira JB. Projecting the cost-effectiveness of pertuzumab with trastuzumab and docetaxel in the neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early breast cancer. J Clin Oncol 2014;32(5 Suppl):abstract 642
20. Peppercorn J AA, Zaas DW, George D. Rationing in Urologic Oncology: lessons from Sipuleucel-T for Advanced Prostate Cancer. Urologic Oncology. In Press 2012
21. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
22. Swanson SJ, Meyers BF, Gunnarsson CL, et al. Video-assisted thoracoscopic lobectomy is less costly and morbid than open lobectomy: a retrospective multiinstitutional database analysis. Ann Thorac Surg 2012;93(4):1027-32
23. Greenup RA, Camp MS, Taghian AG, et al. Cost comparison of radiation treatment options after lumpectomy for breast cancer. Ann Surg Oncol 2012;19(10):3275-81
24. Cannon RM, Scoggins CR, Callender GG, et al. Financial comparison of laparoscopic versus open hepatic resection using deviation-based cost modeling. Ann Surg Oncol 2013;20(9):2887-92
25. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract 2014;10(3):162-7
26. Irwin B. G K, I A et al.. Patient experience and attitudes towards addressing the cost of breast cancer care. Oncologist 2014; In Press
27. Shankaran V, Jolly S, Blough D, Ramsey SD. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 2012;30(14):1608-14
28. Jagsi R, Pottow JA, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol 2014;32(12):1269-76
29. Guy GP Jr, Yabroff KR, Ekwueme DU, et al. Estimating the health and economic burden of cancer among those diagnosed as adolescents and young adults. Health Aff (Millwood) 2014;33(6):1024-31
30. Guy GP Jr, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship among adults in the United States. J Clin Oncol 2013;31(30):3749-57
31. Anderson KR, Chambers CR, Lam N, et al. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract 2014. [Epub ahead of print]
32. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7
33. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126(2):529-37
34. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011;29(18):2534-42
35. Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014;32(4):306-11
36. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008;58(1):9-31
37. Chino F, Peppercorn J, Taylor DH Jr, et al. Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 2014;19(4):414-20
38. Kim P. Cost of cancer care: the patient perspective. J Clin Oncol 2007;25(2):228-32
39. Reinhardt UE. The disruptive innovation of price transparency in health care. Jama 2013;310(18):1927-8
40. Cutler D, Dafny L. Designing transparency systems for medical care prices. N Engl J Med 2011;364(10):894-5
41. Kliff S. One hospital charges $8,000 - another, $38,000. Available from: www.washingtonpost.com/blogs/wonkblog/wp/2013/05/08/one-hospital-charges-8000-another-38000/
42. Kullgren JT, Duey KA, Werner RM. A census of state health care price transparency websites. Jama 2013;309(23):2437-8
43. Yabroff KR, Warren JL, Banthin J, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care 2009;47(7 Suppl 1):S64-9
44. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med 2007;4(9):e283
45. Pilkinton M, Brustman L. A survey of physician knowledge and attitudes on hospital billing costs. Obstet Gynecol 2014 (123 Suppl 1):20S-1S
46. Neumann PJ, Palmer JA, Nadler E, et al. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood) 2010;29(1):196-202
47. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol 2007;25(2):233-7
48. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 2009;27(23):3868-74
49. Love D, Custer W, Miller P. All-payer claims databases: state initiatives to improve health care transparency. Issue Brief (Commonw Fund) 2010;99:1-14
50. Korenstein D, Kale M, Levinson W. Teaching value in academic environments: shifting the ivory tower. Jama 2013;310(16):1671-2
51. Wilensky GR. Why 2014 may be the year for physician payment reform. Healthc Financ Manage 2014;68(3):30-2
52. Schnipper LE. Quality oncology practice initiative: an approach to solving the value equation. J Oncol Pract 2014;10(3):219-20
53. Schnipper LE. The rising cost of cancer care: physicians take charge. J Oncol Pract 2012;8(4):e87-8
54. Haviland JS, Owen JR, Dewar JA, et al. The UK. Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14(11):1086-94
55. Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;81(1):59-68
56. Chen RC, Falchook AD, Hendrix LH, Jagsi R. Adoption of hypofractionated radiotherapy for early-stage invasive breast cancer after publication of randomized trials. J Clin Oncol 2014;32(5 Suppl):abstract 6522
57. Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011;29(6):755-60
58. Major US Health plans agree to give consumers free access to timely information about health care prices to foster greater transparency. Available from: www.healthcostinstitute.org/news-and-events/major-us-health-plans-agree-give-consumers-free-access-timely-information-about-heal [Last accessed 20 June 2014]
59. Schilsky RL, Michels DL, Kearbey AH, et al. Building a Rapid Learning Health Care System for Oncology: the Regulatory Framework of CancerLinQ. J Clin Oncol 2014;32(22):2373-9
60. Arozullah AM, Calhoun EA, Wolf M, et al. The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol 2004;2(3):271-8
61. Markman M, Luce R. Impact of the cost of cancer treatment: an internet-based survey. J Oncol Pract 2010;6(2):69-73